Boston Scientific Co. (NYSE:BSX) Shares Bought by HealthInvest Partners AB

HealthInvest Partners AB lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 45.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 154,222 shares of the medical equipment provider’s stock after acquiring an additional 48,050 shares during the quarter. Boston Scientific makes up about 6.4% of HealthInvest Partners AB’s portfolio, making the stock its 4th biggest holding. HealthInvest Partners AB’s holdings in Boston Scientific were worth $13,831,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in BSX. MONECO Advisors LLC grew its position in Boston Scientific by 13.1% in the fourth quarter. MONECO Advisors LLC now owns 4,365 shares of the medical equipment provider’s stock worth $390,000 after buying an additional 504 shares during the last quarter. Howard Capital Management Inc. boosted its stake in shares of Boston Scientific by 5.6% during the 4th quarter. Howard Capital Management Inc. now owns 9,431 shares of the medical equipment provider’s stock worth $842,000 after acquiring an additional 499 shares in the last quarter. Wealthspire Advisors LLC grew its holdings in shares of Boston Scientific by 41.9% in the 4th quarter. Wealthspire Advisors LLC now owns 6,009 shares of the medical equipment provider’s stock worth $537,000 after acquiring an additional 1,773 shares during the last quarter. Fisher Funds Management LTD acquired a new stake in shares of Boston Scientific during the fourth quarter worth $94,710,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Boston Scientific by 16.2% during the fourth quarter. First Horizon Advisors Inc. now owns 7,469 shares of the medical equipment provider’s stock valued at $667,000 after purchasing an additional 1,044 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.9 %

Shares of BSX stock opened at $104.44 on Monday. The company has a market capitalization of $154.12 billion, a price-to-earnings ratio of 83.55, a PEG ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock’s 50 day simple moving average is $97.98 and its 200 day simple moving average is $89.49. Boston Scientific Co. has a twelve month low of $65.52 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at $23,764,033.92. This trade represents a 22.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 139,630 shares of company stock worth $14,467,616 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of analyst reports. Citigroup lifted their price target on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Canaccord Genuity Group lifted their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. raised their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Royal Bank of Canada raised their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.